60 Degrees Pharmaceuticals, Inc. Common Stock Total Assets
60 Degrees Pharmaceuticals, Inc. Common Stock total assets. Based on the latest financial reports, 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) holds total assets worth $4.28 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 60 Degrees Pharmaceuticals, Inc. Common market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
Total assets of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. This chart illustrates how 60 Degrees Pharmaceuticals, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See 60 Degrees Pharmaceuticals, Inc. Common stock price for real-time trading data and today's change.
60 Degrees Pharmaceuticals, Inc. Common Stock - Asset Composition Analysis
60 Degrees Pharmaceuticals, Inc. Common Stock Total Assets Breakdown (December 2025)
60 Degrees Pharmaceuticals, Inc. Common Stock total assets breakdown as of December 2025. 60 Degrees Pharmaceuticals, Inc. Common Stock's total assets of $4.28 Million consist of 91.2% current assets and 8.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.1% |
| Accounts Receivable | $509.64K | 9.5% |
| Inventory | $656.92K | 12.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $224.36K | 4.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how 60 Degrees Pharmaceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of 60 Degrees Pharmaceuticals, Inc. Common to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 60 Degrees Pharmaceuticals, Inc. Common Stock's current assets represent 91.2% of total assets in 2025, a decrease from 93.7% in 2020.
- Cash Position: Cash and equivalents constituted 28.1% of total assets in 2025, up from 7.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 3.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 12.2% of total assets.
60 Degrees Pharmaceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of 60 Degrees Pharmaceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
60 Degrees Pharmaceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.32 | 2.27 | 1.85 |
| Quick Ratio | 1.78 | 1.80 | 0.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.13 Million | $2.15 Million | $541.20K |
60 Degrees Pharmaceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between 60 Degrees Pharmaceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | -6.8% |
| Total Assets | $5.37 Million |
| Market Capitalization | $3.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values 60 Degrees Pharmaceuticals, Inc. Common Stock's assets below their book value (0.62x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: 60 Degrees Pharmaceuticals, Inc. Common Stock's assets decreased by 6.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual total assets of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.37 Million | -6.83% |
| 2024-12-31 | $5.76 Million | -26.01% |
| 2023-12-31 | $7.78 Million | +500.04% |
| 2022-12-31 | $1.30 Million | -6.91% |
| 2021-12-31 | $1.39 Million | -46.53% |
| 2020-12-31 | $2.61 Million | -- |
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications… Read more